Biocon Biologics is transforming patient outcomes by making life-changing therapies more accessible to the world. Through affordable biosimilars, we are reducing the global healthcare burden, increasing treatment options and driving innovation in biologics, to advance health equity, globally.
Our Differentiators
Integrated to Scale
Transform patients’ lives by delivering affordable access to innovative and inclusive healthcare solutions.
BIOCON LEGACY
Biocon’s rich legacy of being at the cutting edge of science is enabling us to enable health equity worldwide.
EXPANSIVE PORTFOLIO
An expansive portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins.
GLOBAL PRESENCE
A commercial footprint stretching to over 100 countries, which includes both advanced and emerging markets.
Our Impact
~5.5 Million
Patients benefit from our biosimilars, annually
~7.3 Billion
Doses of insulins supplied to patients globally since 2004
20 Biosimilars
In the portfolio
8 Biosimilars
Commercialized in global markets
Our Firsts
-
2004
World’s 1st Pichia pastoris technology based rh-Insulin developed and commercialized in India
-
2017
1st company globally to get U.S. FDA approval for bTrastuzumab
-
2018
1st company globally to get U.S. FDA approval for bPegfilgrastim
-
2021
1st company globally to commercialize interchangeable bGlargine in U.S.
-
2024
1st company to get U.S. FDA approval for interchangeable bAflibercept
Our Commitment
At Biocon Biologics, we are driven by a humanitarian purpose to make healthcare affordable and accessible to even the poorest of patients. This philosophy resonates with our Environmental, Social and Governance (ESG) practices, which stand on the five pillars of Patient Equity, People Equity, Environment Equity, Stakeholder Equity, Social Equity.
